Peptides Codex
ENFR
← Home
Incretin mimetic (GLP-1 receptor agonist)

Efpeglenatide

Efpeglenatide is a long-acting GLP-1 receptor agonist built from an exendin-based peptide conjugated to an antibody Fc fragment for extended duration. It has been evaluated in large clinical programs, including the AMPLITUDE-O cardiovascular-outcomes trial, and remains investigational — it is not authorized by Health Canada.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Incretin mimetic (GLP-1 receptor agonist)
Function
Exendin-based, Fc-conjugated long-acting GLP-1 receptor agonist
Context
Investigational; not authorized by Health Canada

A long-acting exendin peptide extended by Fc conjugation — studied in large cardiovascular-outcome trials.

Also known as: SAR439977 · LAPS-Exendin

Part of the Metabolic & GLP-1 peptides cluster

Overview

Efpeglenatide is a long-acting GLP-1 receptor agonist built from an exendin-based peptide conjugated to an antibody Fc fragment for extended duration. It has been evaluated in large clinical programs, including the AMPLITUDE-O cardiovascular-outcomes trial, and remains investigational — it is not authorized by Health Canada.

Source & context

Biological / chemical source: Engineered exendin-4 analog conjugated to an antibody Fc fragment (LAPSCOVERY platform)

Primary research or clinical context: Investigational; not authorized by Health Canada

Half-life by Fc conjugation

Efpeglenatide pairs an exendin-4-derived peptide with an immunoglobulin Fc fragment via a flexible linker (the developer's LAPSCOVERY platform). Attaching the Fc slows clearance and supports infrequent dosing — a third distinct half-life-extension strategy alongside fatty-acid acylation and albumin fusion seen in other GLP-1 agonists.

Development and status

Efpeglenatide has been studied in a broad clinical program, most notably the AMPLITUDE-O trial evaluating cardiovascular outcomes in type 2 diabetes. Approval status varies by jurisdiction and over time; it is investigational and not authorized by Health Canada. This page is educational and is not treatment advice.

FAQ about Efpeglenatide

What is Efpeglenatide?+

Efpeglenatide is a long-acting GLP-1 receptor agonist built from an exendin-based peptide conjugated to an antibody Fc fragment for extended duration. It has been evaluated in large clinical programs, including the AMPLITUDE-O cardiovascular-outcomes trial, and remains investigational — it is not authorized by Health Canada.

Is Efpeglenatide an approved medicine?+

Efpeglenatide is discussed here as a research / educational topic. Investigational; not authorized by Health Canada. This is not medical advice.

What is the typical length of Efpeglenatide?+

Efpeglenatide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

Secretin
Hormone
Secretin is a 27-amino-acid hormone released from duodenal S-cells in response to stomach acid entering the small intestine. Discovered by Bayliss and Starling in 1902, it was the first substance ever called a hormone and remains a landmark in the history of endocrinology.
Gastrin
Gut hormone
Gastrin is a peptide hormone released by G-cells of the gastric antrum that stimulates acid secretion from the stomach's parietal cells. Circulating in several lengths such as gastrin-17 and gastrin-34, it is a foundational hormone in digestive physiology and in the study of acid-related disorders.
Lixisenatide
Incretin mimetic (GLP-1 receptor agonist)
Lixisenatide is a synthetic GLP-1 receptor agonist built on the exendin-4 scaffold rather than on human GLP-1. Marketed as Lyxumia and Adlyxin, it is an approved prescription medicine in the EU and United States and a useful case study in how venom-derived peptides are adapted into once-daily therapeutics.
Albiglutide
Incretin mimetic (GLP-1 receptor agonist)
Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.

References & further reading

  1. 1.Wikipedia — Efpeglenatide
  2. 2.ClinicalTrials.gov — AMPLITUDE-O: Effect of Efpeglenatide on Cardiovascular Outcomes (NCT03496298)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Efpeglenatide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.